Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michelle Ashe"'
Autor:
Stephen J. Schuster, Alessandra Cesano, Amy Chadburn, John P. Leonard, Heather Ziccardi, William A. Wegener, Scott Z. Fields, David M. Goldenberg, Urte Gayko, Morton Coleman, Michael W. Schuster, Michelle Ashe, Hans J. Hansen, Richard R. Furman, Jamie C. Ketas, Michael Eschenberg, Eric J. Feldman
Publikováno v:
Clinical Cancer Research. 10:5327-5334
Purpose: We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin’s lymphoma.Experimental Design: E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c1da048c873419297fe8219f2bd9aeb
https://doi.org/10.1158/1078-0432.ccr-04-0294
https://doi.org/10.1158/1078-0432.ccr-04-0294
Autor:
J. M. Fiore, Jamie C. Ketas, Amy Chadburn, William A. Wegener, Heather Horne, Morton Coleman, Ruben Niesvizky, Tsiporah B. Shore, John P. Leonard, Richard R. Furman, C. Ding, Jacqueline Kovacs, David M. Goldenberg, Ivan Horak, Michelle Ashe
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(22)
PurposeTo explore the safety and therapeutic activity of combination anti–B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL).Patients and MethodsTwenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::614d173a86d838727c644ec6f1185ce7
https://pubmed.ncbi.nlm.nih.gov/15955901
https://pubmed.ncbi.nlm.nih.gov/15955901
Autor:
John P, Leonard, Morton, Coleman, Jamie C, Ketas, Amy, Chadburn, Richard, Furman, Michael W, Schuster, Eric J, Feldman, Michelle, Ashe, Stephen J, Schuster, William A, Wegener, Hans J, Hansen, Heather, Ziccardi, Michael, Eschenberg, Urte, Gayko, Scott Z, Fields, Alessandra, Cesano, David M, Goldenberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(16)
We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin's lymphoma.Epratuzumab was administered once
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5c9ae85932e214428cf2b556f5a32e6c
https://pubmed.ncbi.nlm.nih.gov/15328164
https://pubmed.ncbi.nlm.nih.gov/15328164
Autor:
Morton, Coleman, David M, Goldenberg, Abby B, Siegel, Jamie C, Ketas, Michelle, Ashe, Jennifer M, Fiore, John P, Leonard
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(10 Pt 2)
The development of effective B cell-directed monoclonal antibody therapies has dramatically altered the management of patients with B-cell non-Hodgkin's lymphoma. Anti-CD20 murine and chimeric antibodies have been characterized by manageable toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::99663f141a776a223a6f5b48911f9346
https://pubmed.ncbi.nlm.nih.gov/14506198
https://pubmed.ncbi.nlm.nih.gov/14506198
Autor:
John P. Leonard, Morton Coleman, Ruben Niesvizky, Richard R. Furman, J. M. Fiore, Lena Mathews, Jamie C. Ketas, Michelle Ashe
Publikováno v:
Blood. 104:4600-4600
Although considered an indolent disease, marginal zone lymphoma (MZL) often requires treatment. No standard therapy has been clearly established. Mitoxantrone has been effective in combination for indolent lymphomas, and is associated with considerab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0ebb9c76baa715aeb9d7a5ebc2e131a
https://doi.org/10.1182/blood.v104.11.4600.4600
https://doi.org/10.1182/blood.v104.11.4600.4600
Autor:
Morton Coleman, J. M. Fiore, C. P. Sison, Mark S. Lachs, Jamie C. Ketas, John P. Leonard, Richard R. Furman, Abby B. Siegel, L. M. Mathews, Michelle Ashe
Publikováno v:
Journal of Clinical Oncology. 22:8166-8166
8166 Background: Age over 60 and impaired “performance status” (PS) are adverse prognostic features in the International Prognostic Index (IPI) for lymphoma. However, patients over 60 comprise a he...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::294434cef08258d165553a9f7bbbf006
https://doi.org/10.1200/jco.2004.22.90140.8166
https://doi.org/10.1200/jco.2004.22.90140.8166